Objective: Two different algorithms operating in three-dimensional space, one dependent on surface detection developed at Cedars-Sinai Medical Center (CS) and another dependent on statistical parameters and developed at Stanford University Medical School (SU), were compared in the same patients to assess the left ventricular volumes and the left ventricular ejection fractions (LVEFs) from gated single-photon emission tomography (SPECT) myocardial perfusion images.
Methods: Perfusion SPECT images gated in eight time bins were recorded in 40 patients with coronary artery disease 60 minutes after the injection of 925 MBq 99mTc-labeled tetrofosmin at rest. The LVEF values were validated against planar gated 99mTc-labeled blood pool studies (ERNA).
Results: The software success rates were 95% (38/40 patients) for CS and 100% for SU. Agreement between LVEFs measured with CS and SU and agreement between both methods and ERNA were excellent (LVEF[CS] = 0.89LVEF[SU] + 6.21, r = 0.93; LVEF[SU] = 0.92LVEF[ERNA] + 0.99, r = 0.94; and LVEF[CS] = 0.88LVEF[ERNA] + 4.58, r = 0.93). Bland-Altman plots showed that differences between LVEFs from SU and CS and from ERNA were similar across a wide range (20% to 80%) of LVEF values. No relationship between these differences and the severity of perfusion defects was observed. For left ventricular volumes, linear regression analysis showed an excellent correlation between both methods (end-diastolic volume r = 0.97 end-systolic volume r = 0.98), but systematically higher values were obtained with SU (p = 0.013).
Conclusion: Measurements of LVEF obtained with CS and SU correspond well with those from the standard, ERNA, even in patients with severe perfusion defects. A close relationship is observed between SU and CS when left ventricular volumes are considered. Measurements of LVEF (and left ventricular volumes) should be considered as an integral part of myocardial perfusion studies whenever possible.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1071-3581(97)90004-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A new HCM heart sound classification method based on weighted bispectrum features.
Phys Eng Sci Med
January 2025
School of Electrical Engineering and Electronic Information, Xihua University, Chengdu, China.
Hypertrophic cardiomyopathy (HCM), including obstructive HCM and non-obstructive HCM, can lead to sudden cardiac arrest in adolescents and athletes. Early diagnosis and treatment through auscultation of different types of HCM can prevent the occurrence of malignant events. However, it is challenging to distinguish the pathological information of HCM related to differential left ventricular outflow tract pressure gradients.
View Article and Find Full Text PDF[Catheter ablation in patients with heart failure-who benefits?].
Herzschrittmacherther Elektrophysiol
January 2025
Klinik für Elektrophysiologie/Rhythmologie, Ruhr-Universität Bochum, Bochum, Deutschland.
Atrial fibrillation (AF) ablation is associated with a lower likelihood of death and surgical heart failure (HF) interventions in patients with HF. This effect is mainly driven by reduced all cause and cardiovascular death following ablation. Ablation also results in improved left ventricular (LV) function, decreased AF burden and AF regression.
View Article and Find Full Text PDFBerlin Heart EXCOR sVAD implantation technique for neonates and infants with functionally univentricular ductal-dependent systemic circulation.
Multimed Man Cardiothorac Surg
January 2025
Congenital Heart Center, Division of Cardiovascular Surgery, Department of Surgery, University of Florida, Gainesville, FL, USA.
The Berlin Heart EXCOR is a pulsatile paracorporeal ventricular assist device (VAD) for neonates, infants, children and adults with congenital or acquired severe ventricular dysfunction. Berlin Heart EXCOR VADs are routinely used as either a bridge to a cardiac transplantation, or occasionally as a bridge to ventricular recovery. Our programmatic philosophy is to bridge neonates and infants with functionally univentricular ductal-dependent systemic circulation or functionally univentricular ductal-dependent pulmonary circulation who are at high risk for staged palliation because of important cardiac risk factors with a single-ventricle VAD (sVAD) as a bridge to a cardiac transplant.
View Article and Find Full Text PDFPredictive Value of Left Atrial Strain for Thrombotic Events in Hypertrophic Cardiomyopathy without Atrial Fibrillation.
Radiol Cardiothorac Imaging
February 2025
From the Department of Cardiology (L.P., W.J., J.L., W.Q., Y.X., Y.K., Q.Z., Y.C.), Department of Geriatrics (K.W.), and Center of Rare Diseases (Y.C.), West China Hospital, Sichuan University, No. 37, Guo Xue Road, Chengdu, Sichuan 610041, China; and Wexner Medical Center, College of Medicine, The Ohio State University, Columbus, Ohio (Y.H.).
Purpose To assess the predictive value of left atrial (LA) fast long-axis strain derived from cardiac MRI for thrombotic events (TEs) in individuals with hypertrophic cardiomyopathy (HCM). Materials and Methods This secondary analysis of an ongoing prospective trial (Chinese Clinical Trial Registry: ChiCTR1900024094) included consecutive participants with HCM without atrial fibrillation (AF) who underwent cardiac MRI from January 2012 to December 2020. The LA fast long-axis strain was obtained by semiautomatically tracking the distance between the atrioventricular junction and the midposterior LA wall.
View Article and Find Full Text PDFCardiac sarcoidosis; update for the heart failure specialist.
Curr Opin Cardiol
January 2025
Division of Cardiology, University of Ottawa Heart Institute, University of Ottawa, Faculty of Medicine, Tier 1 Clinical Research Chair in Cardiac Electrophysiology, Ottawa, ON, Canada.
Purpose Of Review: This review presents contemporary data on epidemiology, common presentations, investigations and diagnostic algorithms, treatment and prognosis. It particularly focuses on topics of most relevance to heart failure specialists, including what left ventricle (LV) function changes can be expected after treatment and outcomes to all standard and advanced heart failure therapies.
Recent Findings: Around 5% of sarcoidosis patients have clinically manifest cardiac sarcoidosis (CS), presenting with significant arrhythmias (such as conduction disturbances and ventricular arrhythmias) or newly developed unexplained heart failure.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!